CClinicalTrials.gg
CompletedNCT00548392Updated Dec 31, 2008

Sonographic Visibility of Breast Biopsy Marker Clips Up to 4 Weeks After Placement

An observational study in Breast Cancer, sponsored by Fred Hutchinson Cancer Center. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-12-31.

Sponsored by Fred Hutchinson Cancer Center · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
25
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this study is to determine how long collagen based marker clips remain visible by ultrasound after placement in suspicious breast lesions and if collagen based marker clips can be reliably identified in the operating room and serve as effective guidance for surgical removal of high risk or malignant breast lesions.

Read the detailed description

Many breast cancers and other breast lesions are discovered as a palpable abnormality by patients or their providers during a breast exam. Diagnostic imaging and biopsy of these lesions may reveal high-risk or malignant findings. These palpable lesions can be removed in the operating room by the surgeon using touch as guidance. However, there are many lesions discovered by screening examinations that surgeons cannot palpate. When this occurs, a radiologist will percutaneously place a wire or wires at the site of the breast lesion using sonographic or mammographic guidance. The surgeon then uses the wires as a guide for complete and successful resection of the lesion.

New marker devices have been developed that are sonographically visible. They consist of the standard mammographically visible metallic clip surrounded by a sonographically visible collagen plug. It is hypothesized that radiologists and surgeons can effectively localize the clip with intra-operative ultrasound and then resect the lesion. If so, the pre-operative wire localization procedure could be eliminated. This could improve the patient experience while saving time and money by reducing the number of invasive procedures from 3 (biopsy, wire-localization and operation) to 2 (biopsy and operation).

02

Conditions studied

  • Breast Cancer

Keywords

  • breast
  • cancer
  • ultrasound
  • high risk
  • marker clip
03

In context

Lead sponsor

Fred Hutchinson Cancer Center is the lead sponsor of 537 studies on the registry; 79 are open to participants now.

Of its 57 completed or terminated interventional studies of FDA-regulated products, 45 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

outpatient clinic

Inclusion criteria

  • Patients with suspicious breast lesions that have undergone biopsy and marker clip placement within 28 days (4 weeks) of pre-operative consultation visit.
  • Patients or their legal representative must be able to provide written informed consent.
  • Patients must be over 18 years old.

Exclusion criteria

Exclusion Criteria:

  • Under the age of 18 years
  • Unable to give written informed consent
  • Patients will be excluded if the clip was placed more than 4 weeks prior to their pre-operative appointment or wire-localization.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
25 participants (estimated)
Biospecimen retention
None retained
06

What researchers measure

Primary outcomes

  1. Visibility of marker clip after placement in suspicious breast lesions.

    Time frame: Within 4 weeks of placement

07

Study locations

1 site
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109-1023, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 31, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00548392
Lead sponsor
Fred Hutchinson Cancer Center
Collaborators
Ethicon Endo-Surgery, GE Healthcare
First posted
Oct 24, 2007
Start date
May 2007
Primary completion
Sep 2008
Completion
Sep 2008
Last update
Dec 31, 2008

Study contacts

Peter R Eby, MD
principal investigator · University of Washington

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion